Hematology

Obstetrical manifestations of the antiphospholipid syndrome

Obstetrical manifestations of the antiphospholipid syndrome
Authors
Charles J Lockwood, MD
Peter H Schur, MD
Section Editor
Susan M Ramin, MD
Deputy Editor
Vanessa A Barss, MD
Last literature review version 19.3: Fri Sep 30 00:00:00 GMT 2011 | This topic last updated: Tue Sep 06 00:00:00 GMT 2011 (More)

INTRODUCTION — The antiphospholipid syndrome (APS) refers to a syndrome characterized by arterial or venous thrombosis or specific pregnancy complications in women with laboratory evidence of antibodies to proteins bound to anionic phospholipids. Pregnancy complications that have been associated with APS include pregnancy-related maternal thrombosis, late fetal death, early severe preeclampsia, fetal growth restriction, and recurrent pregnancy loss [1]. The two main types of antiphospholipid antibodies (aPL) of concern to obstetricians are lupus anticoagulants (LA) and anticardiolipin antibodies (aCL) [2], although detection of anti-beta-2-glycoprotein-1 antibodies may be a risk for later miscarriages and/or thromboembolic complications [3].

Pregnancy-related complications associated with APS will be discussed in this review. The evaluation, treatment and monitoring of pregnancies complicated by aPL and general issues related to APS in the nonpregnant population are reviewed separately:

 

  • (See “Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome”.)
  • (See “Clinical manifestations of the antiphospholipid syndrome”.)
  • (See “Diagnosis of the antiphospholipid syndrome”.)
  • (See “Treatment of the antiphospholipid syndrome”.)
  • (See “Pathogenesis of the antiphospholipid syndrome”.)

 

PATHOGENESIS OF ADVERSE PREGNANCY OUTCOME — The role of aPL as a causal factor in pregnancy loss was demonstrated in experiments in which aPL from women with fetal loss was injected into the peritoneal cavity of pregnant mice and caused fetal death [4]. Initially, aPL was believed to cause obstetrical complications primarily by inducing thrombosis in the uteroplacental circulation. Thrombosis could be induced by a variety of pathways [5-12]; as an example, aPL can reduce the levels of trophoblast-associated annexin V, thereby promoting placental villus thrombosis [13-19]. In a murine model, APS appears to increase monocytic expression of tissue factor, the major initiator of coagulation in vivo [20]. If true in humans, this may also play a role in thrombosis and adverse pregnancy outcome [20]. Eicosanoid imbalance and cross reactivity with glycosaminoglycans are other possible prothrombotic mechanisms. Further investigation is required, and studies in humans need to be performed.

Although thrombosis may be one mechanism for adverse pregnancy outcome, not all affected placentas have signs of thrombosis or infarction. Experimental models suggest that additional factors are responsible for adverse pregnancy outcomes [8,21-25]. As an example, complement activation is a critical component of APS-related adverse pregnancy outcomes [26-28]. APL-induced neutrophil tissue factor expression has been linked to induction of placental bed inflammation in an experimental murine model [29]. Interleukin-3 (IL-3), which is an important factor for embryo implantation and placental development, is decreased in pregnant women with APS compared with controls without APS, and in animal models of APS. Mice with APS and low IL-3 have high rates of pregnancy loss that can be partially prevented by treatment with IL-3 [8]. In addition, aPL appears to have a direct effect on human placental trophoblast, inhibiting the expression of human chorionic gonadotrophin, inducing apoptosis, decreasing trophoblast fusion, altering expression of adhesion molecules, limiting trophoblast invasiveness, and inhibiting decidualization of cultured endometrial stromal cells [30-34]. Thus, the association of APS and pregnancy complications may not be just an epiphenomenon occurring after antecedent endothelial injury [4,24,35]. (See “Pathogenesis of the antiphospholipid syndrome”.)

PREVALENCE OF aPL IN PREGNANT WOMEN — The reported prevalence of aCL in women with uncomplicated pregnancies ranges from 0 to 11 percent, with a median value of about 2 percent [36-44].

OBSTETRICAL OUTCOMES

Definitions — An international committee proposed the following criteria for defining adverse pregnancy outcomes in the diagnosis of APS [2]:

 

  • Abortion is the delivery of a pregnancy, either spontaneously (miscarriage) or electively, before 20 weeks of gestation. A first trimester abortion occurs up to 13 weeks of gestation, a second trimester abortion occurs between 14 and 20 weeks.
  • Recurrent pregnancy loss (also known as recurrent abortion) refers to two or more spontaneous abortions (the abortions do not have to be in consecutive pregnancies).
  • Preembryonic loss occurs from conception through the end of the fourth week of gestation.
  • Embryonic loss occurs from the fifth through the ninth week of gestation.
  • Preterm delivery constitutes a live birth or stillbirth after 20 and before 37 weeks of gestation. After this, the birth is considered a term delivery.
  • A fetal demise refers to an intrauterine death at anytime after 10 weeks of gestation. Stillbirth refers to a demise after 20 weeks of gestation.

 

These definitions were proposed because fetal loss and pregnancy loss are imprecise terms used in different ways by different investigators. Fetal loss may be used to refer to an abortion or fetal death at a gestational age defined by the investigator (eg, only after 10 weeks of gestation, only in the second or third trimester). Pregnancy loss can mean an abortion, fetal death at any gestational week, or delivery of an infant of any gestational age that does not survive. The broad usage of these terms for case selection in studies of adverse pregnancy outcome has contributed to variable, and often conflicting, results.

Adverse outcomes — Adverse pregnancy outcomes attributed to the presence of aPL include [1]:

 

  • Late fetal death
  • Early, severe preeclampsia/eclampsia
  • Fetal growth restriction
  • Pregnancy-related maternal thromboembolic disease (venous or arterial)
  • Recurrent pregnancy loss. This a controversial area; many investigators believe aPL antibodies are not a cause of embryonic loss before 10 weeks [39,45,46].

 

Pregnancy complications such as preeclampsia and fetal growth restriction often lead to preterm delivery, which places the neonate at risk of complications of prematurity. (See “Short-term complications of the premature infant” and “Long-term complications of the premature infant”.)

There is no good evidence of an association between aPL and primary infertility [47-51]. Although some studies have reported an increased incidence of in vitro fertilization failure in women with aPL [36,52], a meta-analysis failed to confirm this association [53].

Difficulties with causality — Since aPL can be found in normal asymptomatic individuals, it is sometimes unclear whether there is a causal relationship between these antibodies and a clinical event in any one individual, particularly when the adverse obstetrical outcome is relatively common (eg, spontaneous abortion before 10 weeks). Additional explanations for the poor predictive value of a given positive LA or aCL result include the following:

 

  • Reliance upon non-standardized assays for aPL and failure to use internationally recognized standards
  • Failure to control for the severity of co-existing diseases (eg, systemic lupus erythematosus [SLE], diabetes, renal disease, hypertension, and infections) known to cause adverse obstetrical outcomes
  • Failure to recognize co-existing inherited coagulopathies (see “Inherited thrombophilias in pregnancy”)
  • Inclusion of patients with low positive aPL levels among patients considered positive
  • Broad definitions for case selection in series involving pregnancy wastage (preembryonic versus later loss)
  • The variable thrombogenic potential of a given patient’s aPL
  • Population heterogeneity in concentrations of clotting, anti-clotting, and fibrinolytic proteins
  • Population heterogeneity with respect to the clinical phenotype of APS, which may be recurrent early pregnancy loss, late pregnancy loss, thrombosis, or premature birth before 34 weeks of gestation because of eclampsia, preeclampsia, or placental insufficiency [54].
SEE MORE:  Chronic anticoagulation after acute coronary syndromes

 

Recurrent abortion and fetal loss — There is good evidence that aPL are associated with late fetal loss (10 or more weeks of gestation), and that subsequent pregnancies are at increased risk of recurrent fetal loss [33,55,56]. There appears to be a correlation between the level of IgG aCL and the risk of pregnancy loss [57]. Although many women with aPL also have systemic lupus erythematosus (SLE), the risk of pregnancy loss appears to be independent, at least in part, of their underlying autoimmune disease. A review of 10 studies involving 554 women with SLE found fetal loss was more common among those with than among those without aPL (38 to 59 percent versus 16 to 20 percent), LA (36 versus 13 percent), or aCL (39 versus 18 percent) [58].

In addition, a meta-analysis including 2000 women without autoimmune disease found a significant association between aPL and pregnancy loss before 13 and before 24 weeks of gestation; this association was stronger for LA (OR 13) than for Ig-G aCL (OR 3.6) or Ig-M aCL (OR 5.6) [56].

Some studies suggest there is also an association between aPL and preembryonic (less than 6 weeks of gestation) and embryonic (6 through 9 weeks of gestation) loss [33,46,59,60], while other studies fail to establish a link [61]. Causality is difficult to establish since there are many disorders associated with recurrent pregnancy loss. (See “Definition and etiology of recurrent pregnancy loss”.)

The risk of aPL and fetal loss was examined in a cohort of 491 patients with a history of adverse pregnancy outcomes [46]. These women were evaluated for both aCL and LA, as well as inherited thrombophilias. The presence of a maternal thrombophilia was found to be protective of recurrent losses at <10 weeks of gestation (OR 0.55, 95% CI 0.33-0.92), but was associated with a modestly increased risk of loss >10 weeks (OR 1.76, 95% CI 1.05-2.94). Women who experienced only euploid losses were not more likely to have an identified thrombophilia than women who experienced only aneuploid losses (OR 1.03; 95% CI 0.38-2.75).

The paradoxical observation that maternal thrombophilias, including aPL, might be protective of early loss is not unexpected [46]. Early pregnancy is normally associated with a low oxygen environment, trophoblast plugging of the intervillous space, and low Doppler flow of the uteroplacental circulation [62,63]. Thus, the early pregnancy environment may be relatively immune to the effects of aPL.

Fetal growth restriction — The best evidence of an association between aPL and growth restriction derives from a prospective study of 860 unselected Japanese women evaluated for aCL in the first trimester [64]. The rate of fetal growth restriction was significantly higher among the 60 aCL positive than the 800 aCL negative women (12 versus 2 percent) [64].

Among patients with symptomatic APS, the frequency of growth restriction approaches 30 percent, which is significantly higher than the rate of 10 percent or less observed in the general population [65,66].

Preeclampsia/HELLP — Systematic reviews have concluded there is a significant association between the development of preeclampsia and the presence of aCL [33,67], and possibly LA [33]. For aCL, the odds ratios were 2.73 (95% CI 1.65-4.51) [33] and 2.86 (95% CI 1.37-5.98) [67] and, for LA, the odds ratio was 1.45 (95% CI 0.70-4.61) [33]. Severe preeclampsia and HELLP syndrome (Hemolysis, Elevated Liver function enzymes, and Low Platelet count) are particular concerns in this population [64,67-73], while mild or near term/term preeclampsia does not appear to be strongly associated with aPL [70].

Maternal thrombosis — Pregnancy and the puerperium are associated with an increased incidence of thromboembolic disease, including stroke. The risk of thromboembolism among aPL positive patients is highly variable and is exacerbated by co-existent hereditary coagulopathies (eg, factor V Leiden) [65,74], but aPL is likely to increase the risk of pregnancy-related venous thrombosis [72,75]. In a cohort study, 24 percent of thrombotic events in women with aPL occurred in association with pregnancy [76]. In a prospective study, the risk of thrombosis during pregnancy was 5 percent among women with known APS (compared with 0.025 to 0.10 percent in the general obstetrical population) [66]. (See “Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis”.)

Risk in unselected populations — Whether asymptomatic women with aPL and no prior adverse pregnancy outcome (no thrombotic event or pregnancy complication) have an increased risk of complications during pregnancy is unclear.

Some studies show little or no increase in risk:

 

  • Among 1449 healthy pregnant women, positive aCL tests occurred infrequently and were rarely associated with adverse pregnancy outcome [38].
  • An elegant study comparing women with spontaneous abortion or fetal death with pregnant controls also found no association between aPL and an adverse pregnancy outcome [39]. Among 331 women with spontaneous abortion or fetal death and 993 control women, no increased risk of miscarriage was observed in first pregnancies in women with aPL. This study concluded that routine screening of women with one pregnancy loss for aPL was not indicated.

 

In contrast, a prospective study of asymptomatic nulliparas with normal pregnancies reported a higher rate of fetal loss in women found to have high-titer IgG aCL before 25 weeks of gestation than in those who were aCL negative (28 versus 7 percent) [77].

NEONATAL APS — Neonatal APS is defined by the same criteria as APS in other populations: presence of at least one type of aPL in serum and the occurrence of at least one clinical feature such as venous or arterial thromboses or thrombocytopenia [78]. A confounding factor, however, is that aPL in the neonate results from placental transfer of maternal antibody, and thus may not have the same significance as endogenously produced antibody. Passively acquired aPL completely disappears by 6 to 12 months of age [79].

Neonatal APS is rare to nonexistent. Studies reporting neonatal outcome of maternal APS have not described any cases of neonatal APS among 277 neonates [79-84]; a registry that collects outcome data on pregnancies complicated by APS also has not recorded any cases of neonatal APS [85]. However, a literature review found 16 case reports of thrombosis in infants born to women with aPL, and 12 of these infants met criteria for neonatal APS (for the other four infants, aPL was detected only in the mother) [86]. Causality related to aPL has not been established, as almost all of these infants had additional risk factors for arterial or venous thrombosis (eg, asphyxia, sepsis, indwelling vascular catheters, cardiac disease, inherited thrombophilia, antenatal disorders [preeclampsia, growth restriction]).

WHEN TO EVALUATE FOR ANTIPHOSPHOLIPID ANTIBODIES — Given the confusion surrounding causality and association with adverse outcomes, the population that should be evaluated for aPL because of obstetrical complications is controversial.

 

  • The American College of Obstetricians and Gynecologists recommends testing women with “appropriate medical or obstetrical histories” for APS [1].
  • The American College of Chest Physicians Evidence-Based Clinical Practice Guidelines recommend that women with recurrent early pregnancy loss (three or more miscarriages) be tested for the presence of LA and aCL antibodies [72]. They also suggest screening women with severe or recurrent preeclampsia or fetal growth restriction, while acknowledging that there is less evidence supporting this approach. Since they consider late fetal death an appropriate indication for treatment with anticoagulants, women with otherwise unexplained late fetal loss should be screened for aPL.
SEE MORE:  Heparin-induced thrombocytopenia

 

If the initial screening test is positive, it should be repeated in 12 weeks to determine whether the aPL is transient or persistent. (See “Diagnosis of the antiphospholipid syndrome”.)

Evaluation for aPL is also indicated in nonpregnant women and women with no history of pregnancy complications if other clinical manifestations of APS are present or if they have SLE. (See “Clinical manifestations of the antiphospholipid syndrome”.)

SUMMARY AND RECOMMENDATIONS

 

  • Thrombus formation, infarction, and vasculopathy are assumed to account for many of the clinical manifestations of the APS, but additional factors, such as direct effects on trophoblast, may also play a role in adverse pregnancy outcomes. (See ‘Pathogenesis of adverse pregnancy outcome’ above.)
  • We suggest that patients with the following pregnancy complications be tested for the presence of LA and aCL antibodies:

 

 

  • One or more fetal losses after 10 weeks of gestation
  • Unexplained intrauterine growth restriction
  • Early, severe preeclampsia
  • Pregnancy-related maternal thrombosis

 

(See ‘When to evaluate for antiphospholipid antibodies’ above.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin #68: Antiphospholipid syndrome. Obstet Gynecol 2005; 106:1113.
  2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295.
  3. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009; 113:985.
  4. Branch DW, Dudley DJ, Mitchell MD, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163:210.
  5. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41:179.
  6. De Wolf F, Carreras LO, Moerman P, et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142:829.
  7. Ogishima D, Matsumoto T, Nakamura Y, et al. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies. Pathol Int 2000; 50:224.
  8. Fishman P, Falach-Vaknine E, Zigelman R, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91:1834.
  9. Cosgriff TM, Martin BA. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 1981; 24:94.
  10. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76:101.
  11. Pötzsch B, Kawamura H, Preissner KT, et al. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125:56.
  12. Cariou R, Tobelem G, Bellucci S, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells–inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60:54.
  13. Rand JH, Wu XX, Guller S, et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171:1566.
  14. Rand JH, Wu XX, Guller S, et al. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177:918.
  15. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome–a possible thrombogenic mechanism. N Engl J Med 1997; 337:154.
  16. Krikun G, Lockwood CJ, Wu XX, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15:601.
  17. Rand JH, Arslan AA, Wu XX, et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol 2006; 194:182.
  18. Römisch J, Schorlemmer U, Fickenscher K, et al. Anticoagulant properties of placenta protein 4 (annexin V). Thromb Res 1990; 60:355.
  19. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264:7944.
  20. Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009; 113:4101.
  21. Katsuragawa H, Rote NS, Inoue T, et al. Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts. Am J Obstet Gynecol 1995; 172:1592.
  22. Di Simone N, Raschi E, Testoni C, et al. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005; 64:462.
  23. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110:2423.
  24. Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci U S A 1993; 90:6464.
  25. Cervera R, Balasch J. Autoimmunity and recurrent pregnancy losses. Clin Rev Allergy Immunol 2010; 39:148.
  26. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211.
  27. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196:167.e1.
  28. Tincani A, Cavazzana I, Ziglioli T, et al. Complement activation and pregnancy failure. Clin Rev Allergy Immunol 2010; 39:153.
  29. Girardi G. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clin Rev Allergy Immunol 2010; 39:160.
  30. Di Simone N, De Carolis S, Lanzone A, et al. In vitro effect of antiphospholipid antibody-containing sera on basal and gonadotrophin releasing hormone-dependent human chorionic gonadotrophin release by cultured trophoblast cells. Placenta 1995; 16:75.
  31. Di Simone N, Ferrazzani S, Castellani R, et al. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod 1997; 12:2061.
  32. Di Simone N, Caliandro D, Castellani R, et al. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999; 14:489.
  33. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132:171.
  34. Pericleous, C, Rahman, A, Giles, I. Do antiphospholipid antibodies have direct pathologic effects upon endometrial and trophoblast cells? Curr Rheumatol Rep 2009. [Epub ahead of print].
  35. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991; 88:3069.
  36. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35:151.
  37. Polzin WJ, Kopelman JN, Robinson RD, et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 1991; 78:1108.
  38. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991; 165:1272.
  39. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 1991; 325:1063.
  40. Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161:369.
  41. Petri M. Diagnosis of antiphospholipid antibodies. Rheum Dis Clin North Am 1994; 20:443.
  42. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991; 34:1231.
  43. Petri M, Golbus M, Anderson R, et al. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum 1987; 30:601.
  44. Haddow JE, Rote NS, Dostal-Johnson D, et al. Lack of an association between late fetal death and antiphospholipid antibody measurements in the second trimester. Am J Obstet Gynecol 1991; 165:1308.
  45. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87:489.
  46. Roqué H, Paidas MJ, Funai EF, et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91:290.
  47. Stern C, Chamley L, Norris H, et al. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril 2003; 80:376.
  48. Porter TF. Antiphospholipid antibodies and infertility. Clin Obstet Gynecol 2001; 44:29.
  49. Hornstein MD. Antiphospholipid antibodies in patients undergoing IVF: the data do not support testing. Fertil Steril 2000; 74:635.
  50. Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update 2008; 14:359.
  51. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril 2009; 92:1803.
  52. Stern C, Chamley L, Hale L, et al. Antibodies to beta2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study. Fertil Steril 1998; 70:938.
  53. Hornstein MD, Davis OK, Massey JB, et al. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000; 73:330.
  54. Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19:58.
  55. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10:3301.
  56. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33:2214.
  57. Loizou S, Byron MA, Englert HJ, et al. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988; 68:525.
  58. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.
  59. Geis W, Branch DW. Obstetric implications of antiphospholipid antibodies: pregnancy loss and other complications. Clin Obstet Gynecol 2001; 44:2.
  60. Chauleur C, Galanaud JP, Alonso S, et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010; 8:699.
  61. Backos M, Rai R, Regan L. Antiphospholipid antibodies and infertility. Hum Fertil (Camb) 2002; 5:30.
  62. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 1992; 80:283.
  63. Jaffe R. Investigation of abnormal first-trimester gestations by color Doppler imaging. J Clin Ultrasound 1993; 21:521.
  64. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86:555.
  65. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14:131.
  66. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614.
  67. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:1433.
  68. Alsulyman OM, Castro MA, Zuckerman E, et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol 1996; 88:644.
  69. Le Thi Thuong D, Tieulié N, Costedoat N, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005; 64:273.
  70. Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001; 184:825.
  71. American College of Obstetricians and Gynecologists. Antiphospholipid syndrome. ACOG educational bulletin 244. ACOG 1998; Washington, DC.
  72. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:844S.
  73. Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP Syndrome and Its Relationship with Antiphospholipid Syndrome and Antiphospholipid Antibodies. Semin Arthritis Rheum 2011.
  74. Montaruli B, Borchiellini A, Tamponi G, et al. Factor V Arg506–>Gln mutation in patients with antiphospholipid antibodies. Lupus 1996; 5:303.
  75. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991; 66:520.
  76. Silver RM, Draper ML, Scott JR, et al. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994; 83:372.
  77. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994; 120:470.
  78. Tincani A, Rebaioli CB, Andreoli L, et al. Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 2009; 11:70.
  79. Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol 2006; 23:247.
  80. Pollard JK, Scott JR, Branch DW. Outcome of children born to women treated during pregnancy for the antiphospholipid syndrome. Obstet Gynecol 1992; 80:365.
  81. Botet F, Romera G, Montagut P, et al. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med 1997; 25:192.
  82. Ruffatti A, Dalla Barba B, Del Ross T, et al. Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol 1998; 16:605.
  83. Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med 1999; 27:183.
  84. Tincani A, Lojacono A, Taglietti M, et al. Pregnancy and neonatal outcome in primary antiphospholipid syndrome. Lupus 2002; 11:649.
  85. Boffa MC, Aurousseau MH, Lachassinne E, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus 2004; 13:713.
  86. Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus 2007; 16:634.
SEE MORE:  Clinical manifestations of paroxysmal nocturnal hemoglobinuria